Sol-Gel Technologies to Present at Upcoming Cantor Virtual Global Healthcare Conference

Rhea-AI Summary

Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) has announced its participation in the virtual Cantor Global Healthcare Conference from September 27-30, 2021. During this event, Dr. Alon Seri-Levy and CFO Gilad Mamlok will engage in a fireside chat discussion on September 30, starting at 10:40 a.m. ET. The discussion will be available on demand, and a replay can be accessed for 30 days. Sol-Gel focuses on developing topical dermatology treatments, leveraging proprietary technologies for products like TWYNEO and EPSOLAY. For more information, visit their official website.

NESS ZIONA, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will participate in the Cantor Global Healthcare Conference, taking place virtually from September 27^th – 30^th, 2021.

Cantor Global Healthcare Conference Presentation Information:
Format	Fireside chat discussion and 1-on-1 meetings
Speaker:	Dr. Alon Seri-Levy, Chief Executive Officer and Mr. Gilad Mamlok, Chief Financial Officer
Date:	Thursday, September 30th
Time:	Discussion available on demand beginning Thursday, September 30th 10:40 a.m. ET (TRACK 3)
To Listen	To listen to the discussion, click here. A replay will be archived for 30 days at this link (or go to www.sol-gel.com to access within the Investors/Events and Presentations section).

About Sol-Gel Technologies

Sol-Gel is a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for TWYNEO, which is FDA approved for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older; and EPSOLAY, under investigation for the treatment of inflammatory lesions of rosacea with an NDA filed with the FDA and a PDUFA goal date that was set for April 26, 2021. Action on the NDA for EPSOLAY has not yet been taken due to the inability of the FDA to conduct a pre-approval inspection of the production site of EPSOLAY as a result of COVID-19 travel restrictions. Both product candidates are exclusively licensed for U.S. commercialization with Galderma.

The Company’s pipeline also includes early-stage topical drug candidates SGT-210 (erlotinib gel) under investigation for the treatment of palmoplantar keratoderma, SGT-310 (tapinarof cream, 1%) and SGT-510 (roflumilast) under investigation for the treatment of plaque psoriasis and other dermatologic indications.

For additional information, please visit www.sol-gel.com.

Contact:

Irina Koffler
Investor relations, LifeSci Advisors
ikoffler@lifesciadvisors.com
+1-917-734-7387

Sol-Gel Technologies
Gilad Mamlok
Chief Financial Officer
gilad.mamlok@sol-gel.com

FAQ

When is Sol-Gel Technologies participating in the Cantor Global Healthcare Conference?

Sol-Gel Technologies will participate in the Cantor Global Healthcare Conference from September 27 to 30, 2021.

Who will represent Sol-Gel Technologies at the conference?

Dr. Alon Seri-Levy and CFO Gilad Mamlok will represent Sol-Gel Technologies during the conference.

What time is Sol-Gel Technologies' discussion at the conference?

The discussion will be held on September 30 at 10:40 a.m. ET.

How can I listen to Sol-Gel Technologies' presentation?

To listen to the presentation, click on the provided link in the PR, or visit the Sol-Gel website to access the investor section.

What products does Sol-Gel Technologies focus on?

Sol-Gel Technologies focuses on developing branded and generic topical drug products for skin diseases, including treatments for acne and rosacea.